Trending:
Comment
-
17 October 2018
How will the UK’s relaxed cannabis regulations impact clinical practice?
The UK home secretary announced that as of November 1, specialist doctors will be given the option to legally prescribe patients cannabis-based products if their patients would benefit from the...
-
16 October 2018
Trial design should give Dermira’s AD drug a better shot at Phase IIb success
Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should...
-
16 October 2018
Roche’s Hemlibra: a (Bi)-specific shift in the hemophilia A market
The hemophilia drug market is currently undergoing major changes due to advances in recombinant protein engineering, as well as the introduction of gene therapy and novel strategies to target the...
-
15 October 2018
Roche makes a cautious investment in Ionis’ dAMD drug
Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx,...
-
15 October 2018
ESMO 2018: previewing high-impact, late-breaking abstracts
The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical...
-
15 October 2018
Could Brazilian-style incentives boost the US biosimilar market?
Nearly 10 years after the Biologics Price Competition and Innovation Act of 2009 created an abbreviated pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-approved...
-
12 October 2018
AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL
A 7.5-year follow-up of AbbVie and Johnson & Johnson’s Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) found that the seven-year progression-free survival (PFS) rate is more than 90% for low-risk...
-
11 October 2018
Almirall brings new drug to stagnant US acne market
On October 2, the FDA approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older. Seysara was originally...
-
11 October 2018
AbbVie’s risankizumab has uptake caveats despite anticipated approvals
AbbVie’s risankizumab for moderate-to-severe plaque psoriasis will likely face market hurdles despite highly expected regulatory approvals.
-
10 October 2018
Promising therapies in the breast cancer pipeline
Breast cancer is one of the most common forms of cancer worldwide, with approximately 5.4 million cases worldwide in 2016.
